NYSE:MYOVMyovant Sciences Stock Price, Forecast & News

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYOV shares have increased by 42.6% and is now trading at $12.41. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myovant Sciences.

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Myovant Sciences.

Myovant Sciences Ltd (NYSE:MYOV) issued its quarterly earnings data on Monday, May, 18th. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.04. View Myovant Sciences' earnings history.

5 Wall Street analysts have issued 1-year price targets for Myovant Sciences' stock. Their forecasts range from $15.00 to $34.00. On average, they anticipate Myovant Sciences' share price to reach $24.00 in the next year. This suggests a possible upside of 93.4% from the stock's current price. View analysts' price targets for Myovant Sciences.

News stories about MYOV stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myovant Sciences earned a news impact score of -1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMyovant Sciences.

Myovant Sciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 3,030,000 shares, an increase of 11.0% from the March 31st total of 2,730,000 shares. Based on an average daily trading volume, of 902,400 shares, the short-interest ratio is currently 3.4 days. Currently, 9.4% of the company's shares are sold short. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Energy Transfer LP Unit (ET), Amarin (AMRN), NVIDIA (NVDA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Carnival (CCL), Coty (COTY), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD) and Micron Technology (MU).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (5.25%), Wellington Management Group LLP (3.57%), Cormorant Asset Management LP (2.90%), Victory Capital Management Inc. (2.71%), Victory Capital Management Inc. (2.71%) and Lord Abbett & CO. LLC (2.11%). Company insiders that own Myovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang and Sciences Ltd Roivant. View institutional ownership trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Wellington Management Group LLP, Victory Capital Management Inc., Victory Capital Management Inc., OneAscent Financial Services LLC, Raymond James & Associates, UBS Group AG, and Janus Henderson Group PLC. Company insiders that have sold Myovant Sciences company stock in the last year include Frank Karbe, Kim Sablich, and Matthew Lang. View insider buying and selling activity for Myovant Sciences.

MYOV stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Ikarian Capital LLC, Two Sigma Investments LP, Connor Clark & Lunn Investment Management Ltd., Ghost Tree Capital LLC, and Deutsche Bank AG. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Frank Karbe, Kathleen Sebelius, Mark Altmeyer, and Sciences Ltd Roivant. View insider buying and selling activity for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $12.41.

Myovant Sciences has a market capitalization of $1.12 billion. The company earns $-288,990,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.

The official website for Myovant Sciences is myovant.com.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3351 or via email at [email protected]